- Home
- PHVS vs TRVI Comparison
PHVS vs TRVI Comparison
Compare PHVS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHVS | TRVI |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PHVS | TRVI |
|---|---|---|
| Price | $26.36 | $11.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $40.70 | $20.38 |
| AVG Volume (30 Days) | 99.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.51 | $4.85 |
| 52 Week High | $29.80 | $14.39 |
Technical Indicators
Market Signals| Indicator | PHVS | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 45.42 |
| Support Level | $24.05 | $10.04 |
| Resistance Level | $28.43 | $11.78 |
| Average True Range (ATR) | 1.16 | 0.74 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 32.41 | 22.50 |
Price Performance
Historical ComparisonAbout PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.